Illumina Inc. ($ILMN) Stock Forecast: Up 4.5% Today

What is Illumina Inc.?

Illumina (ILMN) is a leading biotechnology company specializing in genetic sequencing and array-based technologies for analysis. The company is known for its innovative products in the life sciences industry.

Why is Illumina Inc. going up?

ILMN stock is up 4.5% on Dec 9, 2024 15:38

• The strong bullish movement in ILMN today could be attributed to positive market sentiment and potential investor optimism.
• A 9.3% decline since the last earnings report may have sparked interest among investors looking for a potential rebound opportunity.
• Investors might be speculating on positive future earnings estimates or expecting new developments in Illumina's technology and product offerings.
• Overall, the bullish movement in ILMN today could be a result of renewed confidence in the company's growth prospects and potential for a rebound from previous setbacks.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina ( ILMN ) Down 9.3% Since Last Earnings Report: Can It Rebound?

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

https://www.zacks.com/stock/news/2379031/illumina-ilmn-down-93-since-last-earnings-report-can-it-rebound

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

Worldcoin ($WLD) Crypto Forecast: Down 6.2% Today

SushiSwap ($SUSHI) Crypto Forecast: Down 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Up 19.0% Today

Aave ($AAVE) Crypto Forecast: Up 19.1% Today

Avalanche ($AVAX) Crypto Forecast: Up 9.9% Today

Pepe ($PEPE) Crypto Forecast: Down 5.9% Today

Stellar ($XLM) Crypto Forecast: Down 5.0% Today

Sui ($SUI) Crypto Forecast: Up 5.9% Today

Illumina Inc. Price History

13.08.2024 - ILMN Stock was up 6.1%

• Illumina (ILMN) exhibited a notable bullish trend today, likely influenced by:
• Recognition of the stock's impressive long-term performance, drawing in investors seeking stable returns.
• Mention of a recent earnings surge, potentially boosting confidence in the company's growth outlook and attracting more buyers.
• Positive market sentiment towards Illumina's innovative technologies and the promising opportunities within the biotech industry.

02.09.2024 - ILMN Stock was up 5.8%

• Illumina's significant surge in the market today can be linked to its remarkable long-term performance, averaging a 20.33% annual return over the last two decades.
• Investor confidence in Illumina's future within the biotechnology industry may be fueling the increased demand for its stock.
• The company's market capitalization of $20.38 billion highlights investors' trust in its innovative technologies and potential for further expansion.
• Taken together, Illumina's consistent market outperformance and ongoing advancements in genetic sequencing likely played a role in today's positive market movement.

22.10.2024 - ILMN Stock was up 5.2%

• Today, Illumina's stock saw an upturn following the announcement of the expansion of its TruSight Oncology portfolio with the release of the TSO 500 v2 assay.
• The market responded favorably to this news, anticipating that the new assay will improve comprehensive genomic profiling (CGP) of tumors, demonstrating Illumina's dedication to advancing cancer research and treatment.
• Investors perceive this expansion as a strategic decision that may drive future revenue growth for Illumina, fostering increased confidence and stock purchases.

04.10.2024 - ILMN Stock was up 3.0%

• Illumina (ILMN) experienced a bullish movement today, likely driven by positive analyst projections for key metrics in its Q3 earnings.
• The long-term outperformance of Illumina in the market, with an impressive average annual return of 21.08% over the past 20 years, has also contributed to investor confidence and interest in the stock.
• The anticipation of strong performance in the quarter ended September 2024, as indicated by analyst forecasts, has further fueled bullish sentiment among investors.
• Overall, Illumina's consistent growth, market leadership in genomics, and positive earnings outlook have propelled the stock to a strong bullish movement today.

09.11.2024 - ILMN Stock was up 4.5%

• The strong bullish movement in ILMN today could be attributed to positive market sentiment and potential investor optimism.
• A 9.3% decline since the last earnings report may have sparked interest among investors looking for a potential rebound opportunity.
• Investors might be speculating on positive future earnings estimates or expecting new developments in Illumina's technology and product offerings.
• Overall, the bullish movement in ILMN today could be a result of renewed confidence in the company's growth prospects and potential for a rebound from previous setbacks.

07.07.2024 - ILMN Stock was up 5.4%

• Better-than-expected second-quarter sales results were reported by Illumina, leading to an increase in analyst forecasts and a bullish movement in the stock.
• Citigroup raised Illumina's stock target and maintained a positive rating due to strong margins, further boosting investor confidence.
• Despite a revenue decline amid market challenges, Illumina managed to improve its margins, which was well-received by investors and contributed to the bullish movement in the stock.
• The positive earnings report and analyst upgrades likely fueled investor optimism and drove the stock higher throughout the trading day.

07.07.2024 - ILMN Stock was up 8.0%

• The bullish movement in Illumina's stock today is attributed to positive news and performance indicators:
• Citigroup raised the stock target and maintained a strong rating based on robust margins.
• Despite market challenges, the company improved its margins, which is likely viewed positively by investors.
• Illumina's Q2 earnings and revenues surpassed estimates significantly, indicating strong financial performance.
• The reported loss in the second quarter might have been overshadowed by the positive aspects of improved margins and exceeding earnings expectations, leading to the bullish market movement.

13.07.2024 - ILMN Stock was down 5.2%

• Illumina reported surpassing Q2 earnings expectations, although it adjusted its 2024 sales forecast downwards, reflecting difficulties within the global macroeconomic landscape.
• Anticipating a decrease in yearly sales within its primary segment due to constraints in biotech funding, Illumina's future outlook is affected.
• Despite the negative stock movement, analysts have raised their price target for Illumina, showcasing faith in the company's potential longevity.
• The downward movement in Illumina's stock is possibly linked to a blend of factors including the mixed earnings report, revised sales forecast, and uncertainties surrounding future demand in the gene sequencing industry amidst biotech funding challenges.

05.07.2024 - ILMN Stock was up 5.3%

• The stock of Illumina experienced a significant bullish movement recently.
• The company's launch of a new oncology menu for NovaSeq X Series customers indicates a focus on expanding its oncology testing capabilities, which might have influenced positive investor sentiment.
• Market anticipation of Illumina outperforming earnings estimates for the quarter ended June 2024 likely supported the bullish trend, reflecting investor confidence in the company's financial performance.
• Negative sentiment expressed towards Illumina on a financial program might have initially caused some uncertainty, but the overall market response has been largely positive, possibly driven by advancements in Illumina's product offerings and financial outlook.

08.07.2024 - ILMN Stock was up 5.6%

• Illumina's shares surged as analysts increased their price targets post strong Q2 results, indicating confidence in the company's performance and growth potential.
• The decision to raise Illumina's stock target, coupled with a maintained strong rating from Citi, underscores a positive view on the company's profitability and margins.
• Despite a revenue dip due to market challenges, Illumina enhanced its margins, demonstrating resilience and effective cost management.
• The upward trend in Illumina's stock value can be attributed to improved financial performance, optimistic analyst predictions, and overall market positivity propelling the stock upwards.

14.07.2024 - ILMN Stock was up 5.6%

• Illumina, Inc. received a reaffirmation of a "Buy" rating, with new product launches boosting the growth outlook, which likely contributed to the bullish movement.
• Despite beating Q2 earnings expectations, Illumina lowered its 2024 sales view, indicating potential concerns about future performance.
• Activist pressure could be driving some market excitement and speculation around potential strategic changes within the company.
• The overall positive sentiment around gene editing stocks and the potential for transformative medicine may have also positively influenced Illumina's stock performance today.

15.07.2024 - ILMN Stock was up 5.1%

• Illumina's solid performance over the past 20 years, with an annualized return of 21.21%, likely contributed to the bullish movement today.
• The reaffirmation of a "Buy" rating by a prominent analyst, citing new product launches boosting growth outlook, could have instilled confidence in investors and further fueled the positive momentum.
• Despite surpassing Q2 earnings expectations, the update on lowering 2024 sales view might have initially caused some concerns but was overshadowed by the overall positive sentiment towards the company.
• The activist pressure from Icahn Enterprises may have initially raised some uncertainties, but the market seemed to focus more on the company's long-term growth potential and resilience.